BofA lowered the firm’s price target on Sanofi to EUR 122 from EUR 134 and keeps a Buy rating on the shares. Sanofi’s 19% selloff post Q3 results Friday following initial FY24 FY25 EPS guidance is “a huge overreaction and creates an attractive opportunity,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- MeiraGTx (NASDAQ:MGTX) Surges After Sanofi’s $30 Million Investment
- Sanofi downgraded to Hold from Buy at Stifel
- Sanofi (NASDAQ:SNY) Plunges after Announcing Healthcare Spin-Off
- Kymera Therapeutics announces first patient dosed in Phase 2 trial of KT-474
- Options Volatility and Implied Earnings Moves Today, October 27, 2023